Two United States government departments, Defense (DoD) and Health and Human Services (HHS), will purchase another one-point-four million doses of Regeneron’s REGEN-COV in response to the increased demand for the antibody cocktail.
In the U. S., REGEN-COV has been approved for emergency use to prevent and treat COVID-19 in people at high risk of developing severe illness.
“DoD and HHS will purchase another 1.4m doses of REGEN-COV.“
Leonard S Schleifer, Regeneron President and CEO, stated: “More than a year and a half into this pandemic, too many people are still being hospitalised and dying due to COVID-19. While vaccination remains the first line of defence to decrease the burden of COVID-19, REGEN-COV is a key tool that reduces the risk of hospitalisation or death by seventy per cent in high-risk individuals when given early in the course of the infection.”